The Phase I study of ASC30 once-daily tablets is a randomized, double-blind, placebo-controlled, single ascending dose (6 cohorts) and multiple ascending dose (3 cohorts, 28 daily oral doses) study to evaluate the safety, tolerability, PK and efficacy of ASC30 in participants with obesity
Latest Information Update: 12 Nov 2024
Price :
$35 *
At a glance
- Drugs ASC 30 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Ascletis
- 24 Sep 2024 New trial record
- 17 Sep 2024 According to Ascletis media release, the Company expects topline data from the study in the first quarter of 2025.
- 17 Sep 2024 Results from cohort 1 (n=8) presented in an Ascletis media release.